CN114746105A - Il-15组合物及其使用方法 - Google Patents

Il-15组合物及其使用方法 Download PDF

Info

Publication number
CN114746105A
CN114746105A CN201980082406.XA CN201980082406A CN114746105A CN 114746105 A CN114746105 A CN 114746105A CN 201980082406 A CN201980082406 A CN 201980082406A CN 114746105 A CN114746105 A CN 114746105A
Authority
CN
China
Prior art keywords
activatable proprotein
polypeptide
proprotein
activatable
masking moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980082406.XA
Other languages
English (en)
Chinese (zh)
Inventor
李子娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proviva Therapeutics Hong Kong Ltd
Original Assignee
Proviva Therapeutics Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proviva Therapeutics Hong Kong Ltd filed Critical Proviva Therapeutics Hong Kong Ltd
Publication of CN114746105A publication Critical patent/CN114746105A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980082406.XA 2018-12-14 2019-12-13 Il-15组合物及其使用方法 Pending CN114746105A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779793P 2018-12-14 2018-12-14
US62/779,793 2018-12-14
PCT/US2019/066287 WO2020123980A1 (en) 2018-12-14 2019-12-13 Il-15 compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CN114746105A true CN114746105A (zh) 2022-07-12

Family

ID=71075819

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980082406.XA Pending CN114746105A (zh) 2018-12-14 2019-12-13 Il-15组合物及其使用方法

Country Status (8)

Country Link
US (1) US20230045048A1 (https=)
EP (1) EP3893917A4 (https=)
JP (2) JP7557465B2 (https=)
KR (1) KR102911817B1 (https=)
CN (1) CN114746105A (https=)
AU (1) AU2019395266A1 (https=)
CA (1) CA3121813A1 (https=)
WO (1) WO2020123980A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180355A1 (zh) * 2024-02-27 2025-09-04 江苏奥赛康生物医药有限公司 Il-15前药与免疫检查点抑制剂的组合

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
MX2022007202A (es) * 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2021257808A2 (en) * 2020-06-17 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
JP2024511387A (ja) 2021-03-16 2024-03-13 シートムエックス セラピューティクス，インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
US20240228585A1 (en) * 2021-05-03 2024-07-11 President And Fellows Of Harvard College Fc-fusion protein therapeutic for the treatment of pancreatitis
EP4580683A2 (en) * 2022-08-31 2025-07-09 Proviva Therapeutics (Hong Kong) Limited Il-15 procytokine antibody fusion proteins
AU2023338694A1 (en) * 2022-09-08 2025-04-03 Cugene Inc. Novel pd1-targeted il-15 immunocytokine and vitokine fusions
WO2024216170A2 (en) * 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2025085744A1 (en) * 2023-10-18 2025-04-24 Memorial Sloan-Kettering Cancer Center Fusion polypeptides and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003085089A2 (en) * 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US20130101555A1 (en) * 2009-02-23 2013-04-25 Cytomx Therapeutics, Inc. Proproteins and Methods of Use Thereof
JP2015509952A (ja) * 2012-02-28 2015-04-02 ザ ユニバーシティ オブ バーミンガム 免疫療法分子および使用
WO2017201352A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
US20180291384A1 (en) * 2017-01-10 2018-10-11 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US20110178279A1 (en) * 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
US20100189651A1 (en) * 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2016004383A1 (en) * 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
WO2016210447A1 (en) * 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
CN110214147A (zh) * 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003085089A2 (en) * 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US20130101555A1 (en) * 2009-02-23 2013-04-25 Cytomx Therapeutics, Inc. Proproteins and Methods of Use Thereof
JP2015509952A (ja) * 2012-02-28 2015-04-02 ザ ユニバーシティ オブ バーミンガム 免疫療法分子および使用
WO2017201352A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
US20180291384A1 (en) * 2017-01-10 2018-10-11 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GYÖRGY VÁMOSI等: "IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells", PROC NATL ACAD SCI U S A, vol. 101, no. 30, 19 July 2004 (2004-07-19), pages 11082 - 11087, XP055719140 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180355A1 (zh) * 2024-02-27 2025-09-04 江苏奥赛康生物医药有限公司 Il-15前药与免疫检查点抑制剂的组合

Also Published As

Publication number Publication date
WO2020123980A1 (en) 2020-06-18
EP3893917A1 (en) 2021-10-20
US20230045048A1 (en) 2023-02-09
EP3893917A4 (en) 2023-01-11
CA3121813A1 (en) 2020-06-18
JP2022513888A (ja) 2022-02-09
KR20210104060A (ko) 2021-08-24
AU2019395266A1 (en) 2021-06-17
KR102911817B1 (ko) 2026-01-14
JP7557465B2 (ja) 2024-09-27
JP2024175026A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
JP7557465B2 (ja) Ｉｌ－１５組成物およびその使用方法
JP7631420B2 (ja) ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法
US20240254184A1 (en) Il-15 fusion proteins and methods of making and using the same
HK40098241A (zh) Il-15融合蛋白以及制备和使用其的方法
TW202500193A (zh) 抗５ｔ４抗原結合結構域、抗體－藥物共軛體及彼等之使用方法
EA052095B1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination